nivo nivo nivo nivo nivo nivo


Alzheimer's / Dementia News From Medical News Today

Latest Health News and Medical News posted throughout the day, every day.

FierceBiotech News

  • Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.

BioWorld Perspectives

news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs

Message from the Founder

"Alzheimer’s disease (AD) and other related neurodegenerative tauopathies remain a tremendous unmet medical need and major socioeconomic concern worldwide.  Despite the strong and continued efforts from the pharmaceutical industry and National Institute of Health (NIH) in the past two decades to develop an effective treatment for AD, the results thus far have been far from promising.  In essence, we still do not have effective and disease-modifying therapies currently available on the market for AD and many of its related tauopathies, especially traumatic brain injuries like chronic traumatic encephalopathy (CTE) observed in soldiers exposed to a blast or a concussive injury and professional athletes participating in contact sports that experience repeated head trauma.  Perhaps the primary explanation for this lack of development of successful therapies for AD is due to our narrow and limited understanding of the underlying disease process, namely, that the beta-amyloid (Aβ) protein and “Aβ Cascade Hypothesis” is central in the cause of AD.  However, the field of AD research is presently clearly in a state of flux and we have begun to understand that the alternative and often neglected target in AD, namely, the Tau protein, is equally if not the more attractive therapeutic target for this disorder.  Thus, we at Innovative NeuroTechnologies, Inc. (INT) have assembled a highly experienced and capable management team along with a group of internationally renowned scientific experts to assist in the further development of our current pipeline of novel preclinical candidates or products against the Tau therapeutic target into clinical trials.  We are very hopeful that by taking an alternative and more innovative therapeutic approach, we will ultimately be successful in our efforts to introduce novel effective and disease-modifying treatments for AD and other tauopathies, which currently is so desperately needed in the ever growing and expanding aging population in developing societies worldwide!"

Shawn Mojtahedian, Ph.D.  
Founder, President & Chief Scientific Officer

Business strategy

Innovative NeuroTechnologies, Inc. (INT) is engaged in the development of disease-modifying biotherapeutics for the treatment of Alzheimer's disease (AD) and other related human tauopathies, such as frontotemporal dementia (FTD) and chronic traumatic encephalopathy (CTE).  INT is currently in the process of developing three novel monoclonal antibodies (mAbs) against three separate and key epitopes of Tau as potential passive immunotherapies to prevent or delay the onset of the cognitive deficits resulting from these neurodegenerative tauopathies.  The choice of biologics as therapeutics significantly reduces the risks associated with development since humanized mAbs have historically demonstrated very little chance of failure in preclinical toxicology or Phase I clinical trials.  Due to the considerable increase in valuation achieved through the successful completion of such a trial, INT will take at least one anti-Tau program into Phase I before partnering or selling the company. 

Contact Us

Innovative NeuroTechnologies, Inc.

430 Goddard
Irvine, CA 92618-4610
Tel: (949) 453-8240
Fax: (949) 453-8241